Jun 3 |
BriaCell Presents Clinical Efficacy Data at ASCO 2024
|
May 30 |
BriaCell Initiates Patient Enrollment in First-in-Human Study of Bria-OTS™ in Advanced Metastatic Breast Cancer
|
May 28 |
BriaCell Announces Clinical Supply Agreement with BeiGene for Bria-OTS First in Human Study
|
May 28 |
BriaCell signs supply agreement with BeiGene for metastatic breast cancer treatment
|
May 24 |
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
|
May 24 |
This BriaCell Therapeutics Insider Increased Their Holding By 55% Last Year
|
May 17 |
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
|
May 15 |
BriaCell falls on $5M stock offering
|
May 15 |
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering
|
Apr 24 |
BriaCell Announces Oral and Poster Presentations at ASCO 2024
|